<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Apovian, Caroline M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">FDA Opens Door to Obesity Pharmacotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">Obesity drugs have eluded the United States Food and Drug Administration (FDA) approval process for 13 years, but with mechanisms of action identified and obesity recognized as a disease, that is changing. This article reviews the history of obesity pharmacology, present options in obesity pharmacotherapy, as well as the discovery of peptide-based mixed agonists based on glucagon.</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>